
Nuvalent (NUVL) Stock Forecast & Price Target
Nuvalent (NUVL) Analyst Ratings
Bulls say
Nuvalent is a promising clinical-stage biopharmaceutical company with a strong portfolio of small molecule therapies targeting key oncogenic drivers in different types of cancer. Its lead assets, zidesamtinib and neladalkib, have shown promising efficacy, tolerability, and resistance mutation coverage in clinical trials, positioning them for potential launches in 2026. Furthermore, Nuvalent has been chosen as an acquisition target by GlaxoSmithKline, further validating the strategic value of its assets. However, as with any investment in the biotechnology sector, there are inherent risks such as systemic, clinical, regulatory, and commercial risks, as well as the need for significant capital to continue developing its pipeline.
Bears say
Nuvalent is downgraded to NEUTRAL due to their proposed acquisition by GSK for $124/share, which is a fair valuation based on their NPV and uncertainties around the positioning of their products. Despite little FTC risk and expected support from shareholders, the long timeline to resolving key investor debates and the lower premium to last closing price and VWAP may limit potential gains for investors.
This aggregate rating is based on analysts' research of Nuvalent and is not a guaranteed prediction by Public.com or investment advice.
Nuvalent (NUVL) Analyst Forecast & Price Prediction
Start investing in Nuvalent (NUVL)
Order type
Buy in
Order amount
Est. shares
0 shares